BI
Bioxytran, Inc.
BIXT · OTC
$0.02 -8.15% (-$0.00)
1M +0.42%
Market Cap $2.18M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.01
53.3% downside
Current Price
$0.021
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIXT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 433.04%
ROE N/A
ROA N/A
Debt
0 /100
High Current ratio 0.00x
Int. coverage -19.09x
Debt/Equity N/A
Stability
17 /100
Unstable Beta 1.88x
EPS volatility 51.55%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIXT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Platt
Employees
2
Headquarters
Needham